Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
58
GH Quote, Financials, Valuation and Earnings
Last price:
$101.47
Seasonality move
:
8.83%
Day range:
$100.58 - $102.72
52-week range:
$30.15 - $112.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.05x
P/B ratio:
32.59x
Volume:
1M
Avg. volume:
2.1M
1-year change:
234.34%
Market cap:
$13.3B
Revenue:
$739M
EPS (TTM):
-$3.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GH
Guardant Health, Inc.
|
$267.8M | -$0.47 | 32.68% | -47.37% | $114.05 |
|
DGX
Quest Diagnostics, Inc.
|
$2.8B | $2.36 | 5.05% | 21.08% | $198.06 |
|
EXAS
EXACT Sciences Corp.
|
$860.7M | $0.08 | 20.65% | -84.17% | $104.56 |
|
ILMN
Illumina, Inc.
|
$1.1B | $1.23 | -0.1% | 4.82% | $125.28 |
|
NTRA
Natera, Inc.
|
$576.7M | -$0.58 | 21.14% | -42.93% | $246.26 |
|
WGS
GeneDx Holdings Corp.
|
$120.5M | $0.11 | 25.98% | -44.8% | $170.89 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GH
Guardant Health, Inc.
|
$102.14 | $114.05 | $13.3B | -- | $0.00 | 0% | 14.05x |
|
DGX
Quest Diagnostics, Inc.
|
$173.53 | $198.06 | $19.3B | 20.36x | $0.80 | 1.82% | 1.81x |
|
EXAS
EXACT Sciences Corp.
|
$101.56 | $104.56 | $19.2B | -- | $0.00 | 0% | 6.18x |
|
ILMN
Illumina, Inc.
|
$131.16 | $125.28 | $20B | 29.39x | $0.00 | 0% | 4.82x |
|
NTRA
Natera, Inc.
|
$229.09 | $246.26 | $31.9B | -- | $0.00 | 0% | 14.60x |
|
WGS
GeneDx Holdings Corp.
|
$130.06 | $170.89 | $3.8B | 2,156.88x | $0.00 | 0% | 9.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GH
Guardant Health, Inc.
|
136.47% | 1.336 | 16.98% | 2.94x |
|
DGX
Quest Diagnostics, Inc.
|
46.79% | 0.042 | 30.05% | 0.90x |
|
EXAS
EXACT Sciences Corp.
|
50.33% | 1.440 | 24.46% | 2.24x |
|
ILMN
Illumina, Inc.
|
51.97% | 2.443 | 17.73% | 1.04x |
|
NTRA
Natera, Inc.
|
13.7% | 1.258 | 0.9% | 3.03x |
|
WGS
GeneDx Holdings Corp.
|
28.13% | 1.811 | 3.68% | 2.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GH
Guardant Health, Inc.
|
$171.6M | -$99M | -36.05% | -8518.58% | -37.33% | -$45.8M |
|
DGX
Quest Diagnostics, Inc.
|
$911M | $420M | 7.41% | 14.33% | 14.92% | $419M |
|
EXAS
EXACT Sciences Corp.
|
$583.9M | $16.3M | -18.87% | -38% | 1.91% | $190M |
|
ILMN
Illumina, Inc.
|
$732M | $231M | 14.3% | 30.55% | 21.33% | $253M |
|
NTRA
Natera, Inc.
|
$384.4M | -$97.6M | -21.88% | -26.6% | -16.48% | $24.5M |
|
WGS
GeneDx Holdings Corp.
|
$79.4M | -$3.1M | 0.56% | 0.82% | -2.68% | $9.6M |
Guardant Health, Inc. vs. Competitors
-
Which has Higher Returns GH or DGX?
Quest Diagnostics, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of 9.13%. Guardant Health, Inc.'s return on equity of -8518.58% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.
Company Gross Margin Earnings Per Share Invested Capital GHGuardant Health, Inc.64.71% -$0.74 $971.9M DGXQuest Diagnostics, Inc.32.35% $2.15 $13.8B -
What do Analysts Say About GH or DGX?
Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.66%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 14.14%. Given that Quest Diagnostics, Inc. has higher upside potential than Guardant Health, Inc., analysts believe Quest Diagnostics, Inc. is more attractive than Guardant Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GHGuardant Health, Inc.17 0 0 DGXQuest Diagnostics, Inc.7 10 0 -
Is GH or DGX More Risky?
Guardant Health, Inc. has a beta of 1.584, which suggesting that the stock is 58.44% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.788%.
-
Which is a Better Dividend Stock GH or DGX?
Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.82% to investors and pays a quarterly dividend of $0.80 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GH or DGX?
Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Guardant Health, Inc.'s net income of -$92.7M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 20.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.05x versus 1.81x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHGuardant Health, Inc.14.05x -- $265.2M -$92.7M DGXQuest Diagnostics, Inc.1.81x 20.36x $2.8B $257M
-
Which has Higher Returns GH or EXAS?
EXACT Sciences Corp. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -2.3%. Guardant Health, Inc.'s return on equity of -8518.58% beat EXACT Sciences Corp.'s return on equity of -38%.
Company Gross Margin Earnings Per Share Invested Capital GHGuardant Health, Inc.64.71% -$0.74 $971.9M EXASEXACT Sciences Corp.68.64% -$0.10 $5B -
What do Analysts Say About GH or EXAS?
Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.66%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.96%. Given that Guardant Health, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Guardant Health, Inc. is more attractive than EXACT Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings GHGuardant Health, Inc.17 0 0 EXASEXACT Sciences Corp.3 18 0 -
Is GH or EXAS More Risky?
Guardant Health, Inc. has a beta of 1.584, which suggesting that the stock is 58.44% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.404, suggesting its more volatile than the S&P 500 by 40.386%.
-
Which is a Better Dividend Stock GH or EXAS?
Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GH or EXAS?
Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Guardant Health, Inc.'s net income of -$92.7M is lower than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.05x versus 6.18x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHGuardant Health, Inc.14.05x -- $265.2M -$92.7M EXASEXACT Sciences Corp.6.18x -- $850.7M -$19.6M
-
Which has Higher Returns GH or ILMN?
Illumina, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of 13.85%. Guardant Health, Inc.'s return on equity of -8518.58% beat Illumina, Inc.'s return on equity of 30.55%.
Company Gross Margin Earnings Per Share Invested Capital GHGuardant Health, Inc.64.71% -$0.74 $971.9M ILMNIllumina, Inc.67.59% $0.97 $5B -
What do Analysts Say About GH or ILMN?
Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.66%. On the other hand Illumina, Inc. has an analysts' consensus of $125.28 which suggests that it could fall by -4.49%. Given that Guardant Health, Inc. has higher upside potential than Illumina, Inc., analysts believe Guardant Health, Inc. is more attractive than Illumina, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GHGuardant Health, Inc.17 0 0 ILMNIllumina, Inc.7 8 1 -
Is GH or ILMN More Risky?
Guardant Health, Inc. has a beta of 1.584, which suggesting that the stock is 58.44% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.855%.
-
Which is a Better Dividend Stock GH or ILMN?
Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GH or ILMN?
Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Guardant Health, Inc.'s net income of -$92.7M is lower than Illumina, Inc.'s net income of $150M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 29.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.05x versus 4.82x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHGuardant Health, Inc.14.05x -- $265.2M -$92.7M ILMNIllumina, Inc.4.82x 29.39x $1.1B $150M
-
Which has Higher Returns GH or NTRA?
Natera, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -14.78%. Guardant Health, Inc.'s return on equity of -8518.58% beat Natera, Inc.'s return on equity of -26.6%.
Company Gross Margin Earnings Per Share Invested Capital GHGuardant Health, Inc.64.71% -$0.74 $971.9M NTRANatera, Inc.64.91% -$0.64 $1.5B -
What do Analysts Say About GH or NTRA?
Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.66%. On the other hand Natera, Inc. has an analysts' consensus of $246.26 which suggests that it could grow by 7.5%. Given that Guardant Health, Inc. has higher upside potential than Natera, Inc., analysts believe Guardant Health, Inc. is more attractive than Natera, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GHGuardant Health, Inc.17 0 0 NTRANatera, Inc.12 2 0 -
Is GH or NTRA More Risky?
Guardant Health, Inc. has a beta of 1.584, which suggesting that the stock is 58.44% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.620, suggesting its more volatile than the S&P 500 by 61.981%.
-
Which is a Better Dividend Stock GH or NTRA?
Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GH or NTRA?
Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Natera, Inc. quarterly revenues of $592.2M. Guardant Health, Inc.'s net income of -$92.7M is lower than Natera, Inc.'s net income of -$87.5M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.05x versus 14.60x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHGuardant Health, Inc.14.05x -- $265.2M -$92.7M NTRANatera, Inc.14.60x -- $592.2M -$87.5M
-
Which has Higher Returns GH or WGS?
GeneDx Holdings Corp. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -6.54%. Guardant Health, Inc.'s return on equity of -8518.58% beat GeneDx Holdings Corp.'s return on equity of 0.82%.
Company Gross Margin Earnings Per Share Invested Capital GHGuardant Health, Inc.64.71% -$0.74 $971.9M WGSGeneDx Holdings Corp.68.04% -$0.27 $406.6M -
What do Analysts Say About GH or WGS?
Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.66%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $170.89 which suggests that it could grow by 31.39%. Given that GeneDx Holdings Corp. has higher upside potential than Guardant Health, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Guardant Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GHGuardant Health, Inc.17 0 0 WGSGeneDx Holdings Corp.7 1 0 -
Is GH or WGS More Risky?
Guardant Health, Inc. has a beta of 1.584, which suggesting that the stock is 58.44% more volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.053, suggesting its more volatile than the S&P 500 by 105.339%.
-
Which is a Better Dividend Stock GH or WGS?
Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GH or WGS?
Guardant Health, Inc. quarterly revenues are $265.2M, which are larger than GeneDx Holdings Corp. quarterly revenues of $116.7M. Guardant Health, Inc.'s net income of -$92.7M is lower than GeneDx Holdings Corp.'s net income of -$7.6M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while GeneDx Holdings Corp.'s PE ratio is 2,156.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.05x versus 9.27x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHGuardant Health, Inc.14.05x -- $265.2M -$92.7M WGSGeneDx Holdings Corp.9.27x 2,156.88x $116.7M -$7.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.4% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.78% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 8.96% over the past day.
